Idenix Pharmaceuticals (IDIX)

[gofishmarko]

>> The phase-3 program for Albuferon includes a whole 900-patient trial just for genotype-2/3 <<

The added bonus is you get to see your results 6 months earlier in the gen2/3 trial.

I've seen studies in which gen-2 patients who achieved RVR ( HCV-neg @ 4wks. ) could be treated for only 12 or 16 wks. and achieve similar SVR rates as those treated for 24 wks. It will be interesting to see if add-ons to SOC can reduce this treatment time even further.